Treatment of Metastatic Disease with Immune Checkpoint Inhibitors Nivolumab and Pembrolizumab: Effect of Performance Status on Clinical Outcomes | Citedby Results | Journal of Immunotherapy and Precision Oncology

Skip to Main Content

Skip Nav Destination

Treatment of Metastatic Disease with Immune Checkpoint Inhibitors Nivolumab and Pembrolizumab: Effect of Performance Status on Clinical Outcomes

Journal of Immunotherapy and Precision Oncology (2022) 5 (2): 37–42.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Prognostic value of the CONUT score with immune checkpoint inhibitors as first‐line therapy for metastatic malignant melanoma

Ken Horisaki
Shusuke Yoshikawa
Shoichiro Mori
Wataru Omata
Arata Tsutsumida
Yoshio Kiyohara

The Journal of Dermatology (2025) 52 (4): 615.

DNA Methylation Signatures Correlate with Response to Immune Checkpoint Inhibitors in Metastatic Melanoma

Julia Maria Ressler
Erwin Tomasich
Teresa Hatziioannou
Helmut Ringl
Gerwin Heller
Rita Silmbrod
Lynn Gottmann
Angelika Martina Starzer
Nina Zila
Philipp Tschandl
Christoph Hoeller
Matthias Preusser
Anna Sophie Berghoff

Targeted Oncology (2024) 19 (2): 263.

Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance

Hannah N. Bell
Weiping Zou

Annual Review of Immunology (2024) 42 (1): 521.

Prognostic value of pretreatment immune inflammation indices in patients with immune-related tumors

Polat Olgun
Omer Diker

Current Medical Research and Opinion (2023) 39 (3): 425.

Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective

Stefano Poletto
Luca Paruzzo
Alessandro Nepote
Daniela Caravelli
Dario Sangiolo
Fabrizio Carnevale-Schianca

Cancers (2023) 16 (1): 101.